Definitive experimental evidence from mouse cancer models and strong correlative clinical
data gave rise to the Cancer Immunoediting concept that explains the dual host-protective …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

During their development and progression tumors acquire numerous mutations that, when
translated into proteins give rise to neoantigens that can be recognized by T cells. Initially …

Highlights•DNA damage and neoantigen formation correlate with local immune activity and
outcome.•Intratumoral heterogeneity affects response to immunotherapy, in part through …

The past decade of cancer research has been marked by a growing appreciation of the role
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Immunotherapeutic manipulation of the antitumor immune response offers an attractive
strategy to target genomic instability in cancer. A subset of tumor-specific somatic mutations …

It is now well established that the immune system can recognize developing cancers and
that therapeutic manipulation of immunity can induce tumor regression. The capacity to …

Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for
treating cancer. The recognition of antigens by immune cells is a crucial step in tumor …